Introduction
The PTEN gene encodes a dual specificity lipid/protein phosphatase which antagonizes the activation of the phosphatidylinositol-3'-OH-kinase (PI3K)/AKT pathway. Mono-and bi-alleleic losses of the PTEN gene has been implicated in prostate cancer progression and inferior clinical outcome (1) (2) (3) (4) (5) (6) .
In a number of models, the PTEN protein mediates its anti-tumorigenic effects via PI3K/AKT-dependent andindependent pathways (7) and PTEN-independent AKT signaling has been implicated in the MRE11-ATM DNA damage response (DDR) (8). Murine embryonic fibroblasts (MEFs) lacking PTEN were recently observed to have high levels of genomic instability and increased endogenous DNA double strand breaks (DSB) associated with a reduction in the expression of RAD51 (a key gene involved in homologous recombination (HR) repair of DSBs). Restoration of PTEN in PTEN -/-MEFs restored RAD51 expression in a manner independent of its phosphatase activity (6). However, subsequent reports in human tumor cell lines have shown conflicting data as to whether PTEN loss is associated with a reduced expression of RAD51 (9, 10). To date, no information exists as to whether PTEN gene status determines RAD51 expression in primary prostate cancers in vivo.
A defined link between PTEN status and HR function in prostate and other human tumors would be important as it would support the treatment for PTEN-null tumors using agents targeted against defects in DNA repair. An example of this approach is the use of inhibitors of poly(ADP ribose) polymerase (PARP) as single agents in germline BRCA1/2-defective ovarian, breast and prostate cancers that are HR-defective (11). The PARP1 and 2 proteins are required for repair of DNA single strand breaks (SSB) and in
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Author Manuscript Published OnlineFirst on November 23, 2011; DOI: 10.1158 /1078 -0432.CCR-11-2189 cells treated with small molecule inhibitors of PARP (PARPi), unrepaired SSBs at replication forks are converted into DSBs which require HR-mediated repair to offset cell lethality. Tumor cells lacking HR function (e.g. deficient in BRCA1 or BRCA2 expression) are exquisitely sensitive to PARPi due the inability to repair replicationassociated DSBs; this results in 'synthetic cell lethality ' (12-15) . The results of clinical trials using PARPi in germline BRCA1-and BRCA2-deficient tumors are promising, but not perfect. It is now recognized that biomarkers that predict functional losses in DNA repair activity, in addition to mutations in DNA repair genes, will be required to more accurately predict clinical PARPi efficacy (11, 16, 17) .
As a potentially important biomarker of DNA repair status, recent reports have suggested that tumor cells that lack PTEN have a marked reduction in RAD51-dependent HR and are therefore sensitive to . This suggests that many sporadic tumors could be amenable to PARPi-specific treatments or other agents that are highly toxic to HR-deficient tumor cells such as mitomycin C (MMC), cisplatinum (cDDP) and ionizing radiation (IR) (21) (22) (23) . Novel trials utilizing PARPi in prostate and other cancers could therefore stratify patients on the basis of intact or abrogated function of the HR, FA, DDR (MRE11-ATM) and now, PTEN pathways (24) (25) (26) . Based on a recent prostate cancer-specific report, they may also be stratified by the presence or absence of aberrant signaling associated with a TMPRSS2:ERG fusion (27, 28) . BRCA2-deficient prostate cancers are particularly aggressive and the use of PARPi in their treatment could help with overcoming castration-resistance (29) . Similarly, as PTEN loss and TMPRSS2:ERG fusions are common events in high-grade and castrateresistant prostate cancers (2), the additional use of PARPi in these tumors would be an Author Manuscript Published OnlineFirst on November 23, 2011; DOI: 10.1158 /1078 -0432.CCR-11-2189 important new therapeutic option (27, 28) .
We previously reported that prostate cancer cells were defective in SSB, DSB, and BER gene expression and selected functional repair endpoints when compared to normal prostate epithelium or stromal cells (30). We therefore evaluated whether PTEN loss in human prostate cancer cells is associated with loss of RAD51 expression and HR and leads to altered clonogenic sensitivity. The current report represents, to our knowledge, the first systematic study of the relationship between PTEN status and RAD51 expression in primary prostate cancers and cell lines.
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siRNA Transfections and Homologous Recombination Assay
Cells were seeded for 18h in 6-well plates such that their density on the day of transfection was ~35%. Cells were transfected with siRNA duplexes to RAD51 (0.25 nM), PTEN (1 nM), or control siRNA using Lipofectamine 2000 (Invitrogen; Carlsbad, CA), according to the manufacturer's instructions. HR-dependent DNA DSB repair was assessed using the DR-GFP/ISce-I assay, as previously described (34).
Western blot analysis
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Clonogenic, Proliferation, and Cell Cycle Assays
Cells were seeded in 6-well plates (two dilutions, in triplicate, per 6-well plate), treated as indicated, and then returned to 37ÛC, 5% CO 2 for the duration of the experiment. Once colonies of >50 cells were observed, the cells were stained with methylene blue for 1h, washed, and then allowed to dry overnight at 37ÛC. Colonies were counted manually and survival calculated as previously described (34).
ATLD fibroblasts (and isogenic fibroblasts expressing either wtMRE11 or an endonuclease-deficient mtMRE11; see (8) for details) were counted manually (using Trypan Blue exclusion to ensure seeding of viable cells) and then seeded in triplicate at a density of ~6500 cells per cm 2 in 6-well plates in the presence of PARP inhibitor (KU-0059436, Olaparib; PARPi) at a final concentration of 1 μM, or in the presence of DMSO as a vehicle control. Cells were harvested by trypsinization at 1, 2, 4, and 8 days postseeding, and cell number was assessed by manual counting using a haemocytometer. For
Author Manuscript Published OnlineFirst on November 23, 2011; DOI: 10.1158 /1078 -0432.CCR-11-2189 cell cycle analyses, cells were stained with propidium iodide and analysed using a FACS Aria flow cytometer, as previously described (35).
PARP Activity Assay
Cells growing in log phase were pre-treated for 1h with 2.5 μM PARPi (or DMSO as control). Cells were lysed in 1X PARP Lysis Buffer from the Universal Chemiluminescent PARP Assay Kit (Trevigen Inc, Gaithersburg, MD). Protein concentrations were determined and PARP activity was assessed using 30 μg of total protein per experimental group, according to the manufacturer's instructions. Activated DNA was omitted from some reactions in order to obtain a measure of basal PARP activity in treated vs. untreated cells.
Primary Prostate Cancer and Xenograft Studies
A tissue microarray (TMA) was constructed using donor cores from 142 radical Author Manuscript Published OnlineFirst on November 23, 2011; DOI: 10.1158 /1078 -0432.CCR-11-2189 H&E sections from each TMA block were scanned using an Aperio ScanScope CS (Aperio, Vista, CA). The digital slides were reviewed to confirm the presence of representative tumor in each donor core and, when applicable, to annotate specific Gleason patterns in each core. Standard clinical follow-up data, representing 7-9 years of follow-up, were compiled for each case represented on the TMA using a UHN RP clinical database. Prostate cancer cell line xenografts and human prostate cancer tissue microarrays were stained with rabbit anti-RAD51 (Santa Cruz Biotechnologies, Santa Cruz, CA) or rabbit monoclonal anti-phospho-AKT (Ser473; Cell Signaling), as previously described (33). In selected studies, the hypoxic biomarker EF5 was injected into tumor-bearing animals prior to sacrifice as previously described (Chan et al.; Can Res; 2010) . RAD51 IHC signal was quantified using a custom algorithm that considers both IHC signal intensity and signal distribution, normalized for total area. Results are presented as arbitrary relative units.
Fluoresence In Situ Hybridization (FISH)
Three color interphase FISH (for PTEN and TMPRSS2:ERG) was applied to formalin-fixed paraffin-embedded (FFPE) prostate cancer TMAs, as previously described (2). Analyses were done using an epi-fluorescence microscope (Zeiss Axio Imager, Gӡttingen, Germany) equipped with a triple bandpass filter set (DAPI/Green/Orange), Reverse transcription PCR (RT-PCR) was performed using the TaqMan Reverse Transcription kit (Applied Biosystems). Quantitative real-time PCR analysis of RAD51 was performed as previously described (34).
UV Laser Microirradiation and Immunofluoresence Microscopy
UV laser microirradiation (UVLM) was performed as previously described (8).
Briefly, cells to be subjected to UVLM were seeded on round #1.5 coverslips, pre-treated with 5-bromo-2'-deoxyuridine (BrdU) for 24h, and then transferred to a humidified, temperature-controlled live cell chamber for irradiation.
Cells were fixed in paraformaldehyde 30min post-irradiation, and double-stained using indicated antibodies.
Nuclei were visualized by staining with 4',6-amidino-2-phenylindole (DAPI).
Stained cells were imaged as previously described (8), using an Olympus Spinning Disk Confocal microscope with a 100x Olympus objective lens, producing 0.16 x 0.16 μm pixels. Z-stacks were obtained at a resolution of 0.25 μm per slice, yielding 0.16 x 0.16 x 0.25 μm voxels. Images were subjected to 3D deconvolution, as previously described (8).
Gene Expression Analyses
Author Manuscript Published OnlineFirst on November 23, 2011; DOI: 10.1158 /1078 -0432.CCR-11-2189 Gene expression analyses in 54 primary castrate-resistant prostate cancers were conducted as previously reported (36), using Complementary DNA-mediated Annealing Selection and Ligation (DASL; Illumina, San Diego, CA).
Statistical Analyses
Quantitative data is shown as the mean +/-one standard error of the mean (SEM) for at least 3 independent experiments. Comparative statistics utilized the paired Student's T-test, Mann-Whitney test, or two-way Analysis of Variance (ANOVA) with Tukey post-hoc tests to evaluate differences between experimental groups. p-values of <0.05 were considered statistically significant.
Results

Lack of PTEN expression or TMPRSS2:ERG fusion Does Not Alter RAD51
Expression in Prostate Cancer Cell Lines or Primary Human Prostate Tumours
Several recent reports have demonstrated that loss of PTEN is often associated with down-regulation of RAD51 (7, 18, 19) , a key regulator of HR-mediated DNA DSB repair. Since PTEN loss is common in human prostate cancer, we evaluated whether PTEN status is associated with differential RAD51 expression in prostate cancer cells.
To that end, we first assessed PTEN and RAD51 protein levels in whole-cell lysates of 22RV1 (PTEN +/+), DU145 (PTEN +/-), and PC3 (PTEN -/-) prostate cancer cells that also vary in TP53 status (31) as functional TP53 has been linked to basal and IR-induced RAD51 expression (37). Table 1 Similar effects were observed in xenografts derived from these cell lines; whereas PTEN loss was associated with increased phospho-AKT immunostaining in these xenografts, there was no differential RAD51 expression in vivo amongst this xenograft panel ( Figure   1A , right panel).
Little data are available on RAD51 expression in vivo in relation to PTEN status in which the microenvironment can alter protein expression. As we had previously shown that hypoxia can down-regulate RAD51 expression (33) intensity and distribution revealed that PTEN loss was not associated with diminished RAD51 expression ( Figure 1D) . Indeed, we observed a significant increase in RAD51 expression in PTEN -/-tumors, relative to PTEN +/+ tumors (p<0.01). RAD51 expression was also unrelated to TMPRSS2:ERG fusion status (Supplemental Figure 1B) . We also compared mRNA expression of PTEN and RAD51 using a public database from a prostate cancer cohort of 218 primary localized and metastatic tumors and xenografts following array CGH and RNA expression studies(5). In this cohort, we found no correlation between reduced PTEN and reduced RAD51 expression (Supplemental A recent report demonstrated that loss of PTEN is associated with sensitivity to PARPi (18), as would be predicted if PTEN loss does, in fact, produce a defect in HR.
However, we did not observe a correlation between PARPi sensitivity and PTEN status in prostate cancer cells, although experimental down-regulation of RAD51 markedly sensitized DU145 cells to PARPi ( Figure 2D) . Indeed, we found that PTEN wild-type 22RV1 cells were the most sensitive of the prostate cancer cell lines to PARPi.
Gottipati and colleagues recently demonstrated that cells with defects in HRmediated DSB repair have elevated PARP activity and are sensitive to PARPi (24).
Since PTEN status has been linked to alterations in HR, and since we observed differential PARPi sensitivity in prostate cancer cells, we next evaluated basal PARP activity in these cell lines in the absence or presence of PARPi; the assay was also 2011; DOI: 10.1158 /1078 -0432.CCR-11-2189 (Supplemental Figure 4B) . Similarly, knockout of PTEN in HCT116 cells did not markedly affect E2F1 binding to the RAD51 promoter (Supplemental Figure 4B) . cells to UV irradiation and to MMC, H 2 O 2 , and methylmethanesulfonate (MMS), but did not affect sensitivity to cisplatin, camptothecin, or taxol ( Figure 4B) . Underscoring the heterogeneity associated with PTEN status, we found that PTEN knock-down or knockout produced a highly variable pattern of mRNA expression of genes involved in the DNA damage response (Supplemental Figure 5 and Supplemental Table 1), and did not produce a gene 'signature' that could be used as a surrogate marker for either PTEN loss or sensitivity to specific DNA damaging agents.
Mendes
Disruption of MRE11 Sensitizes Cells to PARP Inhibition
Previous reports have suggested that PARP1 is required for recruitment of MRE11 to DSB, and that PARP1 interacts with MRE11 to facilitate replication fork restart following DNA replication blocks (26, 42). These data suggest that MRE11 may be an important component of PARP1 biology. Moreover, a recent report demonstrated that PTEN knock-out HCT116 cells have a defect in MRE11 recruitment to DSB (43), consistent with our own findings ( Figure 5A ). For these reasons, we assessed whether MRE11 recruitment to DNA DSB is associated with altered PARPi sensitivity. We subjected 22RV1, DU145, or PC-3 cells to UVLM and monitored MRE11 and γH2AX by immunofluoresence. While MRE11 was recruited to DSB in DU145 and PC-3 cells, we did not observe any recruitment of MRE11 in 22RV-1 cells (Figure 5B ), which were also the most PARPi-sensitive of the prostate cancer cells lines we evaluated (Figure 2) .
We confirmed that MRE11 is down-regulated in 22RV1 cells at the protein and mRNA levels ( Figure 5C and 5D ). To evaluate whether MRE11 can specifically influence PARPi toxicity, we treated MRE11-deficient ATLD fibroblasts (ATLD2) with PARPi, and assessed cell proliferation over 8 days as clonogenic survival experiments were not possible on these cells due to poor plating efficiency. As a control, we performed the same experiment in ATLD fibroblasts expressing either wild-type MRE11 (ATLD2-wtMRE11) or endonuclease-deficient MRE11 (ATLD2-mtMRE11). PARPi significantly attenuated proliferation in ATLD2 fibroblasts, relative to DMSO treatment, an effect that was completely abrogated by reconstitution of either wild-type or mutant MRE11 ( Figure   5E ).
Discussion
Mono-and bi-allelic deletions of the PTEN gene are amongst the most frequently observed molecular aberrations in human cancer. While the vast majority of data surrounding the tumour suppressor role of PTEN pertain to its ability to antagonize the oncogenic PI3K/AKT pathway, recent reports have suggested that disruption of the PTEN gene is associated with reduction in the expression of the homologous recombination factor RAD51 (7, 18, 19) . This suggested that PTEN-mediated tumorigenesis may, in part, be secondary to RAD51-associated genomic instability (7, 18). These findings are potentially of immense clinical importance because of the high frequency of PTEN loss in human tumors, and because they suggest that PTEN loss could potentially be used a biomarker for tumors that may be amenable to treatment with agents that preferentially target HR-deficient cells, including PARPi, IR, MMC or cisplatinum.
Recent studies have suggested that PTEN deletion is a fairly late event during prostate cancer development (5), suggesting that genomic alterations in these tumours may occur Likewise, our isogenic experimental models of PTEN loss (using siRNA or gene knockout) revealed no correlation between PTEN and RAD51 expression. These results contrast with those reported by both Shen and Mendes-Pereira and colleagues (7, 41).
McEllin and colleagues (9) likewise showed no difference in RAD51 mRNA or protein expression in PTEN-null astrocytes vs. wild-type, but did observe a significant decrease in mRNA expression of the RAD51 paralogs RAD51B, C, and D, reduced HR-mediated repair, and sensitivity to MNNG, camptothecin (CPT), and a PARP inhibitor. They furthermore observed that PTEN-null astrocytes were resistant to ionizing radiation, though it is not immediately clear how this can be reconciled with an HR-deficient phenotype, which would be expected to increase radiosensitivity, as we observed in Figure 2C . In contrast, we failed to observe CPT or PARPi sensitivity in our models of PTEN loss. As such, the data presented herein are not consistent with those of Shen, Mendes-Pereira or McEllin (7, 9, 18), with respect to the effect of PTEN loss on RAD51 expression and/or HR capacity, but are consistent with both Gupta and colleagues (10) and with the broader previous literature that has failed to show a correlation between PTEN loss and RAD51 expression. It is possible that the observed disparity results from a complex interaction between PTEN and various DNA damage response and repair pathways, which may be cell and/or tissue-type specific. Nevertheless, it is clear that PTEN status cannot be used universally as a biomarker of either RAD51 expression, HR capacity, or PARPi sensitivity.
In agreement with this, we observed that PTEN status de novo is not a biomarker of RAD51 expression in patients specimens based on FISH and protein expression in 48
Research. 2011; DOI: 10.1158 /1078 -0432.CCR-11-2189 patients with localized disease and RNA expression in 218 patients from a recentlypublished prostate cancer outcomes cohort (5). RAD51 expression (as well as that of other genes previously implicated in the response to PARPi) was also not correlated with PTEN or TMPRSS2:ERG status in a cohort of castrate-resistant prostate cancers. This represents, to our knowledge, the first detailed examination of the expression of RAD51 in primary human prostate cancers with disparate PTEN status. Taken together, these data strongly argue against an association of PTEN or TMPRSS2:ERG status and RAD51 expression in primary prostate cancers. 2011; DOI: 10.1158 /1078 -0432.CCR-11-2189 DSBs following MRE11-ATM activation in a PTEN-independent manner (8). As such, combining biomarkers that reflect MRE11, ATM, BRCA1/2 and AKT status in tumors may provide additional utility to individualize patient treatment strategies based on defective germline or somatic DNA repair in tumors.
Taken together, our data suggest that in prostate cancer, PTEN status is not a biomarker of RAD51 expression or biological activity, or of sensitivity to PARPi, and further suggest that PTEN loss promotes a complex pattern of sensitivity to DNA damaging agents. These findings suggest that further studies will be required to identify novel cellular and molecular biomarkers that predict clinical response to PARPi (e.g.
MRE11).
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